NeurogesX Submits Supplemental new Drug Application for Qutenza (R) 8% Patch for HIV-Associated Peripheral Neuropathy

Biopharmaceutical company, NeurogesX, announced it submitted a supplemental new drug to the US FDA seeking to expand the label to include an application for the management of pain due to HIV-associated neuropathy. FDA Priority Review status is given to drug candidates that offer major advances in treatment and accelerated the standard review time. HIV-PN is the most common neurological complication of HIV infection. READ MORE

Source: Globe Newswire